Hematological Oncology最新文献

{"title":"Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell Lymphoma","authors":"Meirav Kedmi,&nbsp;Elena Ribakovsy,&nbsp;Ohad Benjamini,&nbsp;Ginette Schiby,&nbsp;Iris Barshack,&nbsp;Stephen Raskin,&nbsp;Yael Eshet,&nbsp;Ramit Mehr,&nbsp;Netanel Horowitz,&nbsp;Ronit Gurion,&nbsp;Neta Goldschmidt,&nbsp;Chava Perry,&nbsp;Itai Levi,&nbsp;Ariel Aviv,&nbsp;Katrin Herzog-Tzarfati,&nbsp;Arnon Nagler,&nbsp;Abraham Avigdor","doi":"10.1002/hon.70001","DOIUrl":"https://doi.org/10.1002/hon.70001","url":null,"abstract":"<div>\u0000 \u0000 <p>Therapy for relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (aB-NHL) post autologous stem cell transplantation (ASCT) or in elderly patients can be challenging. In this single-center, single-arm, phase II clinical study, we investigated the efficacy of ibrutinib (560 mg once daily) in combination with bendamustine and rituximab (IBR) given for six 28-day cycles in their standard dose, to patients with R/R aB-NHL who were either transplant ineligible in first or second relapse or post-ASCT for second relapse. The primary endpoint was overall response rate (ORR). Fifty-six patients (54% male, median age 69.7 years) were included. ORR was 49.1% among 55 patients treated with ≥ 1 cycle of IBR and 69.4% among 36 patients treated with ≥ 3 cycles. Patients with relapsed disease had significantly higher ORR compared to those with refractory disease (72.3% vs. 37.8%, <i>p</i> = 0.024). Median overall survival (OS) was 11.6 months (95% CI, 7.1–22.3) and median progression-free survival was 5.3 months (95% CI, 2.5–7.4). Patients with complete and partial responses had significantly longer median OS compared to those with stable and progressive disease (28.1 vs. 5.2 months, <i>p</i> &lt; 0.0001). Adverse events included thrombocytopenia (19.6%), anemia (16.1%), neutropenia (7.1%), fatigue (35.7%), diarrhea (28.6%) and nausea (28.6%). At the first efficacy evaluation 8 patients were referred to transplantation, and 3 more were referred during follow-up. These data indicate that the IBR regimen is a safe and effective treatment option that can also be used for bridging to transplantation in patients with R/R aB-NHL.<b>Trial Registration:</b> ClinicalTrials.gov: NCT02747732</p>\u0000 </div>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 6","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142685360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi-Center Real-Life Study","authors":"M. Picardi,&nbsp;A. Vincenzi,&nbsp;C. Giordano,&nbsp;L. De Fazio,&nbsp;N. Pugliese,&nbsp;A. Scarpa,&nbsp;E. Vigliar,&nbsp;G. Troncone,&nbsp;D. Russo,&nbsp;M. Mascolo,&nbsp;G. Esposito,&nbsp;M. Prastaro,&nbsp;C. Santoro,&nbsp;R. Esposito,&nbsp;C. G. Tocchetti,&nbsp;C. Mainolfi,&nbsp;R. Fonti,&nbsp;S. Del Vecchio,&nbsp;M. Carchia,&nbsp;C. Quagliano,&nbsp;A. Salemme,&nbsp;V. Damiano,&nbsp;R. Bianco,&nbsp;F. Trastulli,&nbsp;F. Ronconi,&nbsp;M. Annunziata,&nbsp;F. Pane","doi":"10.1002/hon.70003","DOIUrl":"10.1002/hon.70003","url":null,"abstract":"<p>In elderly patients with high-risk classic Hodgkin lymphoma (c-HL), we evaluated the impact of a new modality treatment without bleomycin, that is, liposomal doxorubicin (NPLD)-based regimen plus consolidation radiotherapy of residual nodal masses (RNMs), on overall survival (OS) and progression free survival (PFS). In this retrospective study (2013–2023) conducted in tertiary hospitals in the bay of Naples (Italy), 50 older adults (median age, 69 years; range, 60–89) with advanced stage c-HL received frontline treatment with MVD ± irradiation. MVD consisted of 25 mg/m² of NPLD along with standard Vinblastine and Dacarbazine for a total of 6 cycles (twelve iv administrations, every 2 weeks) followed by radiation of RNMs with size ≥ 2.5 cm at computed tomography. Patients underwent MVD with a median dose intensity of 92%. At 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography (FDG-PET), 90% of patients (45/50 patients; one failed to perform final FDG-PET due to early death) reached complete responses. Altogether, 17 patients (34%) received consolidation radiotherapy of RNMs with Deauville score ≥ 3. At 5-year median follow-up, the OS and PFS of the entire population were 87.5% (95% confidence interval [CI], 78.7–97.4) and 81.6% (95% CI, 71.4–93.2), respectively. Eleven patients (22%) experienced grade ≥ 3 adverse events, and 4 of them required hospitalization. Our data suggest that in older adults with high-risk c-HL NPLD-driven strategy (without bleomycin) plus consolidation radiotherapy (if needed) may be a promising up-front option, to test in phase II clinical trials for improving survival incidence.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 6","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia","authors":"Marilisa Galasso,&nbsp;Vittoria Salaorni,&nbsp;Riccardo Moia,&nbsp;Valentina Mozzo,&nbsp;Ester Lovato,&nbsp;Chiara Cosentino,&nbsp;Omar Perbellini,&nbsp;Simona Gambino,&nbsp;Ornella Lovato,&nbsp;Maria Elena Carazzolo,&nbsp;Isacco Ferrarini,&nbsp;Francesca M. Quaglia,&nbsp;Massimo Donadelli,&nbsp;Maria G. Romanelli,&nbsp;Carlo Visco,&nbsp;Mauro Krampera,&nbsp;Gianluca Gaidano,&nbsp;Maria T. Scupoli","doi":"10.1002/hon.70002","DOIUrl":"10.1002/hon.70002","url":null,"abstract":"<p>Chronic lymphocytic leukemia (CLL) is characterized by an extremely variable clinical course. Although several parameters have been shown to be associated with clinical outcomes in patients with CLL, there remains substantial intragroup clinical heterogeneity in otherwise molecularly and staging homogeneous CLL subgroups. We have recently shown that high catalase (CAT) expression identifies patients with an aggressive clinical course and that higher <i>CAT</i> expression is associated with the presence of the rs1001179 single nucleotide polymorphism (SNP) T allele in the <i>CAT</i> promoter. Herein, we genotyped CLL patients for <i>CAT</i> rs1001179 SNP in an exploratory study (<i>n</i> = 235) and in a sequential independent validation study (<i>n</i> = 531). Time-to-event modeling analyses for time-to-first-treatment (TTFT) from the two patients' cohorts showed that TT genotype was associated with a shorter TTFT, independently of other currently used prognostic parameters in CLL. Moreover, the TT genotype identifies CLL patients with a faster clinical progression even within subgroups of patients with low-risk biological and clinical hallmarks. In conclusion, our data show that the TT genotype identifies CLL patients with a shorter TTFT, pointing to this SNP as a possible prognostic factor, which can improve patients' risk stratification leading to better patient management and personalized therapeutic choices.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 6","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect","authors":"Jinrong Yang,&nbsp;Zixu Wang,&nbsp;Kun Wu,&nbsp;Bo Nie,&nbsp;Liyin Li,&nbsp;Jingyan Ruan,&nbsp;Qiang Zhou,&nbsp;Yun Zeng,&nbsp;Mingxia Shi","doi":"10.1002/hon.3316","DOIUrl":"10.1002/hon.3316","url":null,"abstract":"<p>Mutation of isocitrate dehydrogenase 2 (IDH2) is a key factor in promoting cytarabine (Ara-C) resistance in acute myeloid leukemia (AML), however the underly mechanism remains unclear. Acute myeloid leukemia cells, were cultured with either IDH2 knockdown (KD-IDH2) or overexpression (OE-IDH2) to elucidate the role of IDH2 in these leukemic cell lines. Additionally, mutant cell lines were engineered to replicate clinically relevant IDH2 mutations. To investigate cellular responses, the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) was administered to the cells. Cell proliferation was quantified using a Cell Counting Kit-8 (CCK-8), while apoptosis was evaluated through propidium iodide staining followed by flow cytometry. Glycolytic metabolism levels were measured using a specific reagent kit, and Western blotting was employed to determine the expression levels of glycolysis-related proteins. Transcriptome sequencing was conducted to elucidate the mechanisms by which IDH2 mutations influence glycolysis. Furthermore, both in vitro cell experiments and in vivo subcutaneous transplantation tumor models in nude mice were utilized to validate these mechanisms. OE-IDH2 in AML cells, enhances resistance to the Ara-C, promotes cell proliferation and glycolysis, and inhibits apoptosis. KD-IDH2 exhibits opposite effects. Both IDH2 mutations and OE-IDH2 produce similar effects on these cellular processes. The increase in glycolysis levels following IDH2 mutation may contribute to the reduced efficacy of Enasidenib in inhibiting the proliferation of IDH-mutant AML cells. Transcriptome sequencing results indicate an enrichment of the PI3K/Akt signaling pathway in IDH2-mutant AML cells. BEZ235 significantly inhibits the expression of phosphorylated PI3K (p-PI3K), phosphorylated Akt (p-Akt), mTOR, glycolytic metabolism, and Ara-C resistance both in vitro and in vivo. Overexpression and mutation of IDH2 coordinate with the Warburg effect through the PI3K/Akt/mTOR pathway to promote Ara-C resistance in AML.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 6","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3316","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic transplantation for adult T-cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy","authors":"Hidehiro Itonaga,&nbsp;Takuya Fukushima,&nbsp;Koji Kato,&nbsp;Nobuaki Nakano,&nbsp;Takeharu Kato,&nbsp;Takashi Tanaka,&nbsp;Tetsuya Eto,&nbsp;Yasuo Mori,&nbsp;Toshiro Kawakita,&nbsp;Naoyuki Uchida,&nbsp;Machiko Fujioka,&nbsp;Hirohisa Nakamae,&nbsp;Masao Ogata,&nbsp;Satoko Morishima,&nbsp;Takahiro Fukuda,&nbsp;Yoshinobu Kanda,&nbsp;Yoshiko Atsuta,&nbsp;Shigeo Fuji,&nbsp;Makoto Yoshimitsu","doi":"10.1002/hon.3315","DOIUrl":"10.1002/hon.3315","url":null,"abstract":"<p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) provides durable remission for patients with adult T-cell leukemia/lymphoma (ATL); however, few studies have focused on post-transplant outcomes in ATL patients ≤49 years. To clarify prognostic factors in ATL among patients &lt;40 years (adolescents and young adult [AYA]; <i>n</i> = 73) and 40–49 years (Young; <i>n</i> = 330), we conducted a nationwide retrospective study. Estimated 3-year overall survival (OS) rates were 61.8% and 43.1% in AYA and Young patients, respectively (<i>p</i> = 0.005). In the multivariate analysis, Young patients showed worse OS (Hazard ratio (HR) [95% confidential interval] 1.62 [1.10–2.39], <i>p</i> = 0.015), chronic graft-versus-host disease (GVHD)-free and relapse-free survival (CRFS) (HR 1.54 [1.10–2.14], <i>p</i> = 0.011), and GVHD-free and relapse-free survival (GRFS) (HR 1.40 [1.04–1.88], <i>p</i> = 0.026) than AYA patients. No significant differences were observed in OS, CRFS, or GRFS between the myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) regimens; however, non-relapse mortality was significantly lower in patients with the RIC regimen than those with the MAC regimen (HR 0.46 [0.24–0.86], <i>p</i> = 0.015). In summary, OS was worse in Young patients than in AYA patients in the allo-HSCT setting for ATL. Furthermore, the RIC regimen has potential as an alternative treatment option for ATL patients ≤49 years.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 6","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study","authors":"C. Bommier,&nbsp;M. Donzel,&nbsp;C. Rossi,&nbsp;L. M. Fornecker,&nbsp;F. Bijou,&nbsp;A. Chauchet,&nbsp;L. Lebras,&nbsp;L. Ysabaert,&nbsp;C. Haioun,&nbsp;K. Bouabdallah,&nbsp;T. Gastinne,&nbsp;N. Morineau,&nbsp;S. Amorim,&nbsp;F. Jardin,&nbsp;J. Abraham,&nbsp;T. Lamy de la Chapelle,&nbsp;R. Gressin,&nbsp;L. Fouillet,&nbsp;C. Fruchart,&nbsp;G. Olivier,&nbsp;F. Morschhauser,&nbsp;F. Cherblanc,&nbsp;A. Belot,&nbsp;S. Le Guyader,&nbsp;A. Monnereau,&nbsp;H. Ghesquieres,&nbsp;C. Thieblemont","doi":"10.1002/hon.3314","DOIUrl":"10.1002/hon.3314","url":null,"abstract":"<p>Marginal Zone Lymphoma (MZL) comprises three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). Since clinical trials have limited representativeness, there is a need for real-world data (RWD) evidence in MZL. Real-world data in Lymphoma and survival in Adults (REALYSA) is a prospective multicentric French cohort of newly diagnosed lymphoma patients. This study consists of the first abstraction of MZL patients prospectively included in REALYSA between 12/2018 and 01/2021 with at least 1 year of follow-up. It provides a landscape description of clinical characteristics, initial workup, quality of life and first-line therapy performed in routine practice. Among 207 included patients, 122 presented with EMZL, 51 with SMZL and 34 with NMZL. At baseline, median age was 67 years (range 28–96), and patients reported a favorable global health status (75/100 (IQR 58,83)) – which was higher in NMZL and lower in SMZL patients (<i>p</i> = 0.006). ¹⁸FDG-PET/CT was frequently performed at initial workup (EMZL 72%, SMZL 73%, NMZL 85%). Active surveillance was the initial management for 58 (28%) patients. The most prescribed therapies were rituximab-chlorambucil in the EMZL population (30%), rituximab monotherapy in the SMZL population (37%) and R-CHOP (24%)/bendamustine-rituximab (15%) in the NMZL population. At end of first line, overall response rate was 93% among treated patients with 75% of complete response. This French nationwide study provided for the first time prospective RWD on clinical characteristics, initial management and treatment response of MZL patients.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 6","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3314","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142345200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing second line and beyond therapies for primary central nervous system lymphomas","authors":"Brian Primeaux,&nbsp;Chelsea Luo,&nbsp;Erin K. Yeung,&nbsp;Caitlin Linger,&nbsp;Sheree Chen,&nbsp;Bryan Do","doi":"10.1002/hon.3313","DOIUrl":"10.1002/hon.3313","url":null,"abstract":"<p>Primary central nervous system (CNS) lymphoma (PCNSL) is a rare and aggressive lymphoma that affects the CNS without other systemic involvement. High-dose methotrexate (HDMTX)-based regimens are recommended frontline treatment, followed by consolidation with either high-dose chemotherapy, whole brain radiation (WBRT) +/− sequential temozolomide (TMZ), or autologous stem cell transplant (autoSCT). Despite advancements with HDMTX and rituximab, up to half of patients will relapse. Treatment for relapsed or refractory (R/R) disease varies widely as preferred regimens are not well-established. Our study aimed to provide real-world characterization of R/R PCNSL therapies. The secondary objective was characterization of consolidation methods after frontline treatment. This retrospective, descriptive analysis included 54 adult PCNSL patients that received a HDMTX-based frontline regimen between 4/1/2016 and 7/1/2022. Patients receiving HDMTX for the purpose of secondary CNS lymphoma, non-B cell origin PCNSL, and intraocular lymphoma were excluded. Thirty-one patients (57%) received consolidation therapy with rituximab and high-dose cytarabine (R-HDAC), WBRT, or both. Thirteen patients (24%) proceeded with autoSCT. Twenty-five patients had disease progression, with 17 patients receiving second line treatment. The second line treatments were WBRT (24%), clinical trial (18%), rituximab with lenalidomide (R²; 18%), re-induction with HDMTX-based regimens (18%), ibrutinib with rituximab (12%) and R-HDAC (12%). Seven patients progressed, and all received third line treatment. Treatments varied, including R²; ibrutinib +/− HDMTX; rituximab, methotrexate, and cytarabine; R-HDAC; R-nivolumab; and WBRT. Five patients received a fourth line regimen of R +/− lenalidomide, R-HDMTX, or nivolumab monotherapy. Regimens used for the three patients who received fifth line treatment and beyond included R-TMZ and pembrolizumab monotherapy in addition to previously described regimens. Regimen selection is varied and highly dependent on physician preference and patient factors, including clinical trial eligibility, prior therapies, performance status, organ function, and treatment intent. Prospective clinical trials are needed to guide optimal management.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 6","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142345199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Superior prognostic accuracy of FIGO staging system in primary female genital tract lymphomas: A retrospective study (IELSG35)","authors":"Maria Cristina Pirosa,&nbsp;Sara Steffanoni,&nbsp;Anna Vanazzi,&nbsp;Fabiana Esposito,&nbsp;Angela Polino,&nbsp;Alberto Schena,&nbsp;Francesco Landi,&nbsp;Maria Elena Cabrera,&nbsp;Saad Akhtar,&nbsp;Santiago Gardella,&nbsp;Osnat Bairey,&nbsp;Astrid Pavlovsky,&nbsp;Anastasios Stathis,&nbsp;Emanuele Zucca","doi":"10.1002/hon.3312","DOIUrl":"https://doi.org/10.1002/hon.3312","url":null,"abstract":"<p>Primary lymphoma of the female genital tract (PLFGT) is a rare type of extranodal lymphoma. In this retrospective study from the International Extranodal Lymphoma Study Group, we analyzed clinical data from 60 women diagnosed with PLFGT between 1982 and 2012. The median age was 52 years. Limited stage, as defined by the Ann Arbor and FIGO staging systems, was observed in 55% and 63% of cases, respectively. The uterus was the primary site of lymphoma in 25 cases, with the ovaries as the second most common site (<i>n</i> = 24). The most common histological subtype was diffuse large B-cell lymphoma (DLBCL, <i>n</i> = 44), followed by follicular lymphoma and marginal zone lymphoma (6 patients each). Two patients received surgery alone as first-line therapy, while 58 underwent systemic therapy, 16 following major surgery. Thirteen patients received consolidation radiotherapy and six were given central nervous system (CNS) prophylaxis. Twenty patients had disease progression or recurrence. Six patients with DLBCL (14%) experienced CNS relapse, which was the only site of recurrence in five of them. All but one patient with CNS relapse had primary ovarian involvement, and three had bulky disease; none of these patients had received CNS prophylaxis. With a median follow-up of 60 months, the median overall survival of the DLBCL cohort was approximately 13 years, with a 5-year survival rate of 77%. In multivariable analysis, advanced disease according to the FIGO system was the only parameter significantly associated with shorter overall, cause-specific, and progression-free survival in patients with DLBCL.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 6","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3312","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications","authors":"N. Polverelli,&nbsp;M. Anghilieri,&nbsp;C. Elena,&nbsp;T. Intermesoli,&nbsp;E. Pungolino,&nbsp;M. D’Adda,&nbsp;A. Iurlo,&nbsp;M. Maffioli,&nbsp;F. Lunghi,&nbsp;V. Bertolli,&nbsp;N. Orofino,&nbsp;C. Sissa,&nbsp;C. Fiamenghi,&nbsp;A. Gardellini,&nbsp;M. Ubezio,&nbsp;M. C. Carraro,&nbsp;P. Corradini,&nbsp;F. Giglio,&nbsp;M. C. Pasquini,&nbsp;R. Palazzolo,&nbsp;R. Calori,&nbsp;M. Ercolanoni,&nbsp;C. Gambacorti-Passerini","doi":"10.1002/hon.3311","DOIUrl":"https://doi.org/10.1002/hon.3311","url":null,"abstract":"<p>Lombardy represents the largest region of Italy by population, with almost 10 million residents, a dimension similar to a medium size country like Sweden or Belgium. The CML subcommittee of the Lombardy Hematology Network (REL-CML) conducted a study at the beginning of 2023. Prevalence was calculated by direct input from the 21 centers participating in REL-CML. Tyrosine Kinase Inhibitors (TKI) prescription records collected from the ARIA regional registry were used to estimate the number of CML patients followed in smaller centers not participating in REL-CML. A total of 2285 patients were registered, representing a prevalence of 0.23 ‰. These data were compared to a similar census conducted in 2005, at the beginning of the TKI era, where a prevalence of 0.029‰ was calculated. This indicates that an almost 10 times increase took place during this period of time. Imatinib represents the most frequently prescribed first-line TKI; its use in 2022 still represented 75% of total first line prescriptions. An increased concentration of the care of CML patients in specialized REL centers with a decreased dispersion of patients in small centers was also evident over this 18 year period of time. Nineteen % of patients discontinued treatment, highlighting persisting logistical and biological challenges; one some recommendations on CML management are included to this aim.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 5","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3311","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142276632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax","authors":"Stefano Cordella,&nbsp;Davide Giusti,&nbsp;Eleonora De Bellis,&nbsp;Michelina Dargenio,&nbsp;Federica Creti’,&nbsp;Davide Lazzarotto,&nbsp;Chiara Cattaneo,&nbsp;Nicola Stefano Fracchiolla,&nbsp;Matteo Piccini,&nbsp;Fabio Forghieri,&nbsp;Livio Pagano,&nbsp;Anna Candoni","doi":"10.1002/hon.3310","DOIUrl":"https://doi.org/10.1002/hon.3310","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 5","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142234018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}